Great interview Jeramy. I think there is another issue here. When a medication comes off patent and there are genetics then insurance will no longer pay for the name brand patented medication. This is despite clear evidence that many generics just don’t work like the parent medication (see issues around concentra as an example). So while I understand the issues around patent issues don’t we have to also deal with the issues around true measures of comparison between the parent drug and the genetics? Otherwise we are providing cheaper versions of medications that don’t work which is arguably an even worse problem than allowing pharma to protect their patents longer than is prescribed by law
Great interview Jeramy. I think there is another issue here. When a medication comes off patent and there are genetics then insurance will no longer pay for the name brand patented medication. This is despite clear evidence that many generics just don’t work like the parent medication (see issues around concentra as an example). So while I understand the issues around patent issues don’t we have to also deal with the issues around true measures of comparison between the parent drug and the genetics? Otherwise we are providing cheaper versions of medications that don’t work which is arguably an even worse problem than allowing pharma to protect their patents longer than is prescribed by law